Best Practices in Stability Indicating Method Development and Validation for Non-clinical Dose Formulations.
Non-clinical dose formulations (also known as pre-clinical or GLP formulations) play a key role in early drug development. These formulations are used to introduce active pharmaceutical ingredients (APIs) into test organisms for both pharmacokinetic and toxicological studies. Since these studies are ultimately used to support dose and safety ranges in human studies, it is important to understand not only the concentration and PK/PD of the active ingredient but also to generate safety data for likely process impurities and degradation products of the active ingredient. As such, many in the industry have chosen to develop and validate methods which can accurately detect and quantify the active ingredient along with impurities and degradation products. Such methods often provide trendable results which are predictive of stability, thus leading to the name; stability indicating methods. This document provides an overview of best practices for those choosing to include development and validation of such methods as part of their non-clinical drug development program. This document is intended to support teams who are either new to stability indicating method development and validation or who are less familiar with the requirements of validation due to their position within the product development life cycle.
Chemistry and Manufacturing Controls, Sequoia Consulting, 125 N. Acacia Ave, Solana Beach, California, 92075, USA. Teresa.Henry@SequoiaSolution.com.
Teresa R
TR
Henry
Analytical Sciences, Merck Research Laboratories, Rahway, New Jersey, USA.
Lara D
LD
Penn
Formulation Department, MicroConstants, San Diego, California, USA.
Jason R
JR
Conerty
Quality, MicroConstants, San Diego, California, USA.
Francesca E
FE
Wright
McWhorter School of Pharmacy, Pharmaceutical, Social and Administrative Sciences, Samford University, Birmingham, Alabama, USA.
Gregory
G
Gorman
Small Molecule Design and Development, Eli Lilly, Indianapolis, Indiana, USA.
Brian W
BW
Pack
D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000379:methods* / Q000592:standards*; D004304:Dosage Forms / Q000592:standards*; D055808:Drug Discovery / Q000379:methods* / Q000592:standards*; D004355:Drug Stability; D006801:Humans; D015203:Reproducibility of Results
D004304:Dosage Forms
GLP; impurity; non-clinical dose formulation analysis; stability indicating; validation